This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
The Burzynski Clinic (BC) announced today that it made a keynote speaker presentation at the 2
nd Annual Congress of Asia-Pacific Academy of Anti-Aging Medicine in Beijing, China. Based on the presentation in Beijing, a total of 401 eligible patients (patients who received over 28 days of treatment) with advanced inoperable brain tumors have been treated with antineoplaston A10 and antineoplastons AS2-1 therapy (ANP) in phase II studies. Most of the patients (87%) were diagnosed with high-grade tumors and the remaining patients were diagnosed with low-grade tumors. The patients were diagnosed by pathologists not associated with BC and objective responses were verified by Central Radiology Review. The group of 77 patients (19%) survived over five years from the treatment start. Of particular interest were results in patients with brainstem gliomas. The group of 17 patients with brainstem glioma underwent the treatment and 65% of these patients survived over five years. An additional group of 42 patients diagnosed with diffuse intrinsic pontine glioma (DIPG) have been treated and a total of 19% survived over five years.
The quality of survival is very good and there is no long-term toxicity related to ANP.
These clinical results are very encouraging, since they describe a positive ANP effect on some of the worst malignancies in the entire oncology field, but they will require FDA approval.
Burzynski Clinic is committed to developing treatments for cancer based on genomic and epigenomic principles.
Forward-looking statements in this release are made pursuant to the safe harbor provisions of the federal securities laws.Information contained in forward-looking statements is based on current expectations and is subject to change, and future events may differ materially from those discussed herein due to a number of factors, including, but not limited to, risks and uncertainties related to the clinic’s ability to use Antineoplastons A10 and AS2-1.Burzynski Clinic does not undertake to update any such forward-looking statements or to publicly announce developments or events relating to the matters described herein.